To use all functions of this page, please activate cookies in your browser.
With an accout for my.chemeurope.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
Additional recommended knowledge
In the United States, isocarboxazid is approved for the treatment of depression, anxiety (panic disorder) with or without agoraphobia.
In the United Kingdom, isocarboxazid is licensed for the treatment of depression unresponsive to selective serotonin reuptake inhibitors (SSRIs).
A randomized controlled trial published in December of 1988 found that isocarboxazid significantly reduced bingeing and purging in bulimia nervosa, regardless of the presence or absence of depression or personality disorder.
MARPLAN® by Hoffmann-La Roche, starting in 1959 and discontinuing in 1994. After much patient and physician outcry, they resumed manufacturing just enough Marplan® to distribute on an as-needed basis. In October of 1998, Hoffmann-La Roche and Oxford Pharmaceutical Services Inc. announced that Oxford, "is acquiring ownership of the NDA for the antidepressant product Marplan® (isocarboxazid) from Roche."
The maximum daily dose of isocarboxazid is 60mg.
Isocarboxazid is availably generically in the United Kingdom in the form of 10mg tablets. However, it is considered 'less suitable for prescribing' by the British National Formulary (BNF).
|This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Isocarboxazid". A list of authors is available in Wikipedia.|